Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 4Pulmonary Disease, Chronic Obstructive 1Precancerous Conditions 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Standard of Care 3X-Rays 2Educational Status 2Bronchoscopy 2Blood Specimen Collection 2vilanterol 1tocilizumab 1perflutren 1Tomography, X-Ray Computed 1Tiotropium Bromide 1Therapeutics 1Telemedicine 1Tablets 1Symptom Assessment 1Surgical Procedures, Operative 1Sulfur Hexafluoride 1Sulfonylurea Compounds 1Specimen Handling 1Sodium-Glucose Transporter 2 Inhibitors 1Singing 1Salmeterol Xinafoate 1Rehabilitation 1Pulmonary Surgical Procedures 1Prednisolone 1Practice Guidelines as Topic 1Pharmacists 1Palliative Care 1Methods 1Massage 1Magnesium Sulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pulmonary Disease, Chronic Obstructive × Iloprost × Clear all
NCT05411107 2024-05-17

Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

National Cancer Institute (NCI)

Phase 2 Withdrawn
Thoracic

Lung Neoplasms, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡